The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Rethinking Chronic Allograft Nephropathy: The Concept of Accelerated Senescence
Abstract
Chronic rejection or chronic allograft nephropathy (CAN) is the major cause of failure of kidney transplants other than patient death, and has been extensively reviewed (1,2,3,4,5). CAN is characterized by functional impairment with nonspecific pathology: tubular atrophy, interstitial fibrosis, and fibrous intimal thickening (FIT) in the arteries, with variable glomerular lesions. The risk of CAN correlates with the input, immune, and load stresses experienced by that kidney. Input refers to the preexisting chronic conditions in the donor (aging, hypertension) plus the acute injury related to the transplant process (brain death, donor maintenance, organ removal, preservation, implantation, reperfusion). Immune stress is due to rejection by antibody or cellular mechanisms, determined by histocompatibility, presensitization, host responsiveness, and the effectiveness of and compliance with immunosuppression. Load reflects hypertension, donor-recipient size disparity, proteinuria, hyperlipidemia, drug toxicity, and infectious agents. Load factors such as donor size and gender probably reflect differences in nephron dose and are relatively weak, suggesting that nephron number does not explain the strong effect of input and immune factors. What distinguishes the transplant from normal tissue is the level of injury. Injury depletes the finite ability of the tissue to repair, and triggers inflammation, which may further stress the parenchyma and vessels, increase immune recognition, and promote fibrosis. In this article we review the problem of human CAN and propose a model in which the cumulative burden of injury and age exhausts the ability of key cells in epithelium or endothelium to repair and remodel to maintain tissue integrity. We term this exhaustion “senescence” to emphasize the importance of donor aging and the overlap of the pathologic lesions with age-related changes, and to suggest analogy with senescent changes observed in cell culture. When the potential of a tissue to repair is exhausted, the endothelial functions decline and the epithelium atrophies; injury-induced inflammation persists, permitting transforming growth factor-β and other mediators to create fibrosis. Thus, fibrosis may be a default for the failure of normal healing. CAN can be minimized by reducing the burden of injury due to immune and nonimmune mechanisms, but grafts with age- and injury-induced changes may still be useful despite their limitations, and few should be discarded. Recent advances in the cellular basis of senescence in vitro may hold clues to the molecular events that limit the repair of key cells. Development of the Concept of Chronic Rejection and CAN The concept of chronic rejection emerged gradually in the 1950s and 1960s. Acute homograft (now allograft) rejection was well known in the late 1950s in the early clinical experience, and few kidneys survived even for months. In 1955 Hume et al. (6) reported a case in which rejection developed within 5½ mo, with obliteration of the arteries. Systematic investigation of late rejection by Porter et al. (7) and Jeannet et al. (8) revealed that arterial intimal fibrosis was frequent and probably represented a reaction to immune injury, perhaps due to alloantibody (7,9). This may explain the belief that chronic rejection is alloantibody-mediated. Transplant glomerulopathy distinct from recurrent glomerulonephritis was recognized by the late 1960s and early 1970s (10,11,12,13), and is a variable feature of CAN. However, these early observations by Hume, Porter, Jeannet, and their colleagues in transplants on minimal immunosuppression bear little resemblance to the type of late graft loss in the 1990s. The syndrome of obliterative arterial disease progressing over months is now rare, and the clinical course of CAN is usually indolent, with graft loss often many years posttransplant. The arterial lesions are often not prominent in biopsies early in the course. However, the old Hume-Porter-Jeannet syndrome remains the basis of the current animal models of chronic rejection, making them of limited relevance to the clinical problem of CAN. The Problem of Definition We avoid the term chronic rejection because it implies an ongoing immune response that cannot be proven. We cannot determine the extent of immune involvement in CAN at present, and the risk factors indicate a large nonimmune component. Previous efforts to define chronic rejection as a distinct disease often included an arbitrary rate of progression. Such definitions exclude kidneys with poor but stable function, while including kidneys with better function that have experienced recent deterioration. Moreover, progression is often irregular (14), and progression per se is not a criterion for defining other renal diseases. We define CAN as a state of impaired renal allograft function at least 3 mo posttransplant, independent of acute rejection, overt drug toxicity, and recurrent or de novo specific disease entities, wit
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Telomere length predicts replicative capacity of human fibroblasts.
Allsopp, R. C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E. V., Futcher, A. B., Greider, C. W., & Harley, C. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10114 · Cited by 2,200
Epstein, F. H., Brenner, B. M., Meyer, T. W., & Hostetter, T. H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209093071104 · Cited by 2,075
Solez, K., Axelsen, R. A., Benediktsson, H., Burdick, J. F., Cohen, A. H., Colvin, R. B., Croker, B. P., Droz, D., Dunnill, M. S., Halloran, P. F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.259 · Cited by 1,424
Self-citationEffect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
High Survival Rates of Kidney Transplants from Spousal and Living Unrelated Donors
Terasaki, P. I., Cecka, J. M., Gjertson, D. W., & Takemoto, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330601 · Cited by 1,213
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008
Cited by
DNA methylation-based biomarkers and the epigenetic clock theory of ageing
Horvath, S., & Raj, K. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0004-3 · Cited by 3,095
Immunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Self-citationCalcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Strategies to Improve Long-Term Outcomes after Renal Transplantation
Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., & Cosimi, A. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011295 · Cited by 844
Identifying Specific Causes of Kidney Allograft Loss
El-Zoghby, Z. M., Stegall, M. D., Lager, D. J., Kremers, W. K., Amer, H., Gloor, J. M., & Cosio, F. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02519.x · Cited by 801
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D., & SINGER, G. G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11suppl_1s1 · Cited by 634
Humoral Theory of Transplantation
Terasaki, P. I. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00135.x · Cited by 609
Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Chapman, J. R., & Allen, R. D. M. (2004) · Transplantation · doi:10.1097/01.tp.0000128636.70499.6e · Cited by 498
Renal Aging: Causes and Consequences
O’Sullivan, E. D., Hughes, J., & Ferenbach, D. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121308 · Cited by 484
Regele, H., Böhmig, G. A., Habicht, A., Gollowitzer, D., Schillinger, M., Rockenschaub, S., Watschinger, B., Kerjaschki, D., & Exner, M. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000025780.03790.0f · Cited by 423
MYCOPHENOLATE MOFETIL REDUCES LATE RENAL ALLOGRAFT LOSS INDEPENDENT OF ACUTE REJECTION
Ojo, A. O., Meier-Kriesche, H.-U., Hanson, J. A., Leichtman, A. B., Cibrik, D., Magee, J. C., Wolfe, R. A., Agodoa, L. Y., & Kaplan, B. (2000) · Transplantation · doi:10.1097/00007890-200006150-00033 · Cited by 400
Aging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Four-year Follow-up of a Prospective Trial of HLA and MICA Antibodies on Kidney Graft Survival
Terasaki, P., Ozawa, M., & Castro, R. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01644.x · Cited by 362
Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice
Rabb, H., Daniels, F., O'Donnell, M., Haq, M., Saba, S. R., Keane, W., & Tang, W. W. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.279.3.f525 · Cited by 352
Cellular senescence and organismal aging
Jeyapalan, J. C., & Sedivy, J. M. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.04.001 · Cited by 346
Chronic Allograft Nephropathy: Current Concepts and Future Directions
Nankivell, B. J., & Chapman, J. R. (2006) · Transplantation · doi:10.1097/01.tp.0000190423.82154.01 · Cited by 338
Cellular Senescence in the Kidney
Docherty, M.-H., O’Sullivan, E. D., Bonventre, J. V., & Ferenbach, D. A. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018121251 · Cited by 291
Renal Transplantation in Black Americans
Young, C. J., & Gaston, R. S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432107 · Cited by 271
Increased Immunogenicity and Cause of Graft Loss of Old Donor Kidneys
FIJTER, J. W. D., MALLAT, M. J. K., DOXIADIS, I. I. N., RINGERS, J., ROSENDAAL, F. R., CLAAS, F. H. J., & PAUL, L. C. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271538 · Cited by 252
Molecular mechanisms of renal aging
Schmitt, R., & Melk, A. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.036 · Cited by 235
Self-citationTelomere Shortening in Kidneys with Age
MELK, A., RAMASSAR, V., HELMS, L. M. H., MOORE, R., RAYNER, D., SOLEZ, K., & HALLORAN, P. F. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v113444 · Cited by 189
Self-citationEffector Mechanisms of Rejection
Moreau, A., Varey, E., Anegon, I., & Cuturi, M.-C. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015461 · Cited by 189
Melk, A., Schmidt, B. M. W., Vongwiwatana, A., Rayner, D. C., & Halloran, P. F. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00846.x · Cited by 154
Self-citationChkhotua, A. B., Gabusi, E., Altimari, A., D’Errico, A., Yakubovich, M., Vienken, J., Stefoni, S., Chieco, P., Yussim, A., & Grigioni, W. F. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00363-9 · Cited by 120
Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis
Bedi, S., Vidyasagar, A., & Djamali, A. (2008) · Transplantation Reviews · doi:10.1016/j.trre.2007.09.004 · Cited by 100
Molecular events in kidney ageing
Famulski, K. S., & Halloran, P. F. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165890.60254.4e · Cited by 53
Self-citation
Metadata
- Authors
- HALLORAN, P. F., MELK, A., & BARTH, C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1999-01
- Volume
- 10
- Issue
- 1
- Pages
- 167-181
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2149358482
- Cited by
- 452
- References
- 97
- FWCI
- 26.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.